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The arthropod-borne Schmallenberg virus (SBV), family Orthobunyaviridae, emerged in Europe in 2011. SBV is associated
with a mild disease in adult ruminants but fetal malformation after an infection during a critical phase of pregnancy. A
number of inactivated vaccines have been developed; their efficacy after two injections was demonstrated. To make
the vaccination of sheep more efficient and economic the effect of a single immunization with one of these vaccines
was investigated in the present study. Five vaccinated sheep and five additional control sheep were inoculated with
SBV three weeks after vaccination and the results of a competitive ELISA, a standard microneutralization test and an
SBV-specific real-time RT-PCR confirmed vaccine efficacy by demonstrating complete inhibition of viral replication in
immunized animals.Introduction, methods and results
A previously unknown pathogen from the family Ortho-
bunyaviridae emerged in Europe in autumn 2011 and
was named Schmallenberg virus (SBV) according to the
location of its discovery [1]. Midges (Culicoides spp.) are
involved in its transmission [2-4]. While disease was first
observed in cattle, sheep and goats, infection has also
been detected in deer, bison, alpaca, moose and other
wild ruminants [5]. The clinical picture is characterized
by mild febrile disease in adult ruminants and the poten-
tial development of fetal malformations after transplacen-
tal infection [6-9]. An SBV-infection can be confirmed
through detection of viral RNA both in serum during the
first week post infection and in tissue samples [10].
As an effective instrument for disease control different
inactivated vaccines have been developed and tested [11].
Besides, two commercial inactivated vaccines have already
been granted a provisional marketing authorization in the
United Kingdom and France, respectively [12,13].
Until now, only studies about a protective effect after
two vaccinations have been published. Reduction to a
single injection minimizes workload and costs, which is
especially important for sheep owners, as the animals* Correspondence: martin.beer@fli.bund.de
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article, unless otherwise stated.are usually individually caught and restrained on the
pastures for every injection. Therefore, the influence of a
single immunization on a subsequent SBV-inoculation
of sheep was investigated in the present study.
Five SBV-negative yearling sheep (S01 to S05) of Euro-
pean domestic breeds received a single subcutaneous in-
jection with 2 mL of the MA-HT prototype vaccine
from a previous study [11]. Five additional control sheep
(S06 to S10) were left unvaccinated.
Three weeks after vaccination all animals were inocu-
lated with 2 × 0.5 mL of calf serum containing an SBV
field strain that was only passaged in the natural host. The
production of this infectious serum has been described
earlier [10]. The serological status was monitored weekly
by a blocking ELISA (ID Screen® Schmallenberg virus
Competition, ID vet, France) and a standard microneutra-
lization test (SNT) [14]. Additionally, blood samples were
taken daily on the 8 days following challenge infection and
tested by ELISA and an SBV-specific reverse transcription
real-time PCR (RT-qPCR) including an external standard
based on the small (S) genome segment [15]. Rectal body
temperatures were recorded daily during the entire study
and the animals were examined daily for clinical signs.
Autopsy was conducted three weeks after challenge infec-
tion and samples of spleen, mesenteric and mandibulartral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Hechinger et al. Veterinary Research 2014, 45:79 Page 2 of 4
http://www.veterinaryresearch.org/content/45/1/79lymph node and tonsils were taken and tested by
RT-qPCR.
According to German legislation the experimental
protocol was reviewed by a state ethics commission and
has been approved by the competent authority (State
Office for Agriculture, Food Safety and Fisheries of
Mecklenburg-Vorpommern, Rostock, Germany. Ref. No.
LALLF M-V TSD/7221.3-1.1-004/12).
The SBV-antibody-ELISA was used according to the
manufacturer’s instructions. Results were calculated as
the ratio of the optical density (OD) of the sample and
the OD of the negative control (S/N, %). Samples with
an S/N-value of 40% or less were considered positive.
SNT-titers were calculated as reciprocal of the serum di-
lution showing 50% virus neutralization (neutralizing
dose 50, ND50). Titers of 5 or more were considered
positive. The MagAttract Virus Mini M48 Kit (Qiagen.
Germany) was used to extract nucleic acid from serum
and tissue samples according to the manufacturer’s
recommendations.
All animals were serologically and virologically nega-
tive for SBV on the day of immunization. Vaccination
was not associated with adverse side effects. None of the
animals showed clinical signs of disease after challenge
infection; the rectal body temperature remained within a
normal range and autopsy did not reveal any gross
pathological lesions.
On the day of challenge infection all five control ani-
mals were negative for SBV in both serological tests
(Table 1). First SBV-specific antibodies were detected in
controls on day 7 after challenge by SNT and on day 8
after challenge by ELISA. Neutralizing titers rose to
values between 33 and 266 ND50 until day 21 post in-
fection (Table 1).Table 1 Serological results
Animal Group SNTa
0 dpv 14 dpv 0 dpc 7 dpc 14 dpc 21 dp
S01 vac < 5 17 12 10 10 7
S02 vac < 5 56 24 14 10 14
S03 vac < 5 12 7 6 7 14
S04 vac < 5 < 5 < 5 7 7 7
S05 vac < 5 20 28 14 12 12
S06 co ND ND < 5 14 67 40
S07 co < 5 < 5 < 5 12 375 266
S08 co < 5 < 5 < 5 8 160 67
S09 co < 5 < 5 < 5 10 224 160
S10 co < 5 < 5 < 5 8 56 33
Key serological results for vaccinated (vac) and control (co) animals are presented. S
21 days post challenge infection (dpc). Neutralizing titers (SNT) are given as the rec
more were considered positive. ELISA results are calculated as the ratio of the optic
Samples with an S/N value of 40% or less are considered positive. Results for RNA d
aPositive or doubtful ELISA results and positive SNT results are highlighted by boldAll vaccinated animals were positive for SBV prior to
challenge infection in at least one serological test
(Table 1) and, thereafter, neutralizing titers remained
largely constant with values between 7 and 14 ND50 on
day 21 post challenge. The first antibodies were detected
by SNT in S02 on day 7 after vaccination while the
ELISA gave negative results for this animal for all sam-
pling dates except day 14 after vaccination (Table 1).
Samples of S01, S03 and S05 gave positive results in
the SNT starting from day 14 after vaccination while
S01 and S03 scored negative in the ELISA throughout
the study. S05 gave only one doubtful ELISA result on
day 14 post vaccination. In S04 neutralizing antibodies
were detectable only one week after challenge infection
but it scored positive in the ELISA on day 14 after
vaccination and doubtful on the day of challenge
infection.
After challenge infection, SBV-RNA was detectable
in serum samples of all control animals for at least 3
consecutive days (Table 2). The mean maximum gen-
ome load in serum samples was 9.2 × 104 genome cop-
ies per mL. Most tissue samples of the control animals
gave positive PCR results as well. Only tonsils and
mesenteric lymph nodes of S10, and mandibular lymph
nodes of S06 scored negative. Mean genome loads per
gram organ weight were 1.2 × 104 copies/g for man-
dibular lymph nodes (minimum value: 4.9 × 102 copies/g;
maximum value: 3.6 × 104 copies/g), 8.7 × 104 copies/g for
mesenteric lymph nodes (min: 5.9 × 101; max: 3.4 × 105),
1.2 × 105 copies/g for spleens (min: 6.8 × 103; max: 3.9 × 105)
and 1.6 × 105 copies/g for tonsils (min: 4.7 × 101; max:
6.0 × 105).
In contrast, viral RNA was not detected in any serum
or tissue sample from the vaccinated animals.ELISAa qRT-PCR
c 0 dpv 14 dpv 0 dpc 7 dpc 14 dpc 21 dpc tissue
91.6 51.5 53.4 59.6 56.5 53.5 -
92.0 45.8 54.9 55.1 65.6 70.2 -
97.1 50.8 60.1 64.7 51.3 50.1 -
84.4 33.0 42.4 46.0 51.8 56.6 -
92.8 47.5 54.7 57.3 54.6 88.4 -
ND ND 92.5 42.5 26.9 26.5 +
94.9 89.6 94.8 43.8 14.6 17.5 +
95.9 86.7 92.0 30.2 30.6 37.9 +
99.6 91.0 97.3 44.5 23.1 21.9 +
82.4 67.9 73.9 58.8 32.3 27.6 +
erological results are given for 0 and 14 days post vaccination (dpv) to
iprocal of the serum dilution showing 50% virus neutralization. Titers of 5 or
al density (OD) of the sample and the OD of the negative control (S/N, %).
etection are given for tissue samples obtained at autopsy.
figures.
Table 2 RNA detection in serum post challenge
Animal Group Number of SBV-RNA copies per mL serum
0 dpc 1 dpc 2 dpc 3 dpc 4 dpc 5 dpc 6 dpc 7 dpc 8 dpc
S 06 co - - 4.5 × 104 3.9 × 103 2.2 × 103 ND - - -
S 07 co - - 1.9 × 103 1.2 × 104 7.0 × 105 ND 1.4 × 103 - -
S 08 co - - 1.4 × 104 1.5 × 104 2.5 × 104 ND - - -
S 09 co - - 5.2 × 102 3.3 × 104 1.5 × 105 ND - - -
S 10 co - - 8.5 × 102 1.8 × 103 6.4 × 103 ND - - -
Results are given for 0 to 8 days post challenge (dpc) for control animals (co). Dashes represent negative PCR results of the respective samples. Viral RNA was not
detected in the serum of vaccinated animals at any time. Therefore, vaccinated animals were not included in the table. From 5 dpc serum samples were not
available. Consequently, the RNA load could not be determined (ND) for this time point.
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In the unvaccinated control animals PCR results demon-
strated viral replication and dissemination. The serological
results support this observation as the SBV-infection in-
duced a pronounced humoral immune response. In all vac-
cinated sheep, on the other hand, the absence of RNAemia
demonstrates the protective effect of immunization. Fur-
thermore, the antibody titers remained constant which
suggests that the virus is eliminated before a memory im-
mune response with an antibody boost could be triggered.
The latter is in accordance with results of an earlier study
in cattle [14] during which constant neutralizing titers
were detected in seropositive animals after a second ex-
perimental SBV-infection. Interestingly, the single shot
vaccination was highly efficacious and could even prevent
both viremia and infection of target tissues such as mesen-
teric lymphnodes.
Interestingly, neutralizing titers are very low in vacci-
nated animals in this study and only a few ELISA results
of their serum samples exceed the cut-off value. Thus,
further factors, e.g. a cellular immune response, may
contribute to the protective effect of vaccination. Similar
observations have been reported for Rift Valley Fever
virus (RVFV, family Bunyaviridae, genus Phlebovirus).
Neutralizing antibodies are primarily responsible for
protection against RVFV-infection [16]. However, one of
six lambs treated with an inactivated vaccine showed a
reduction in viremia and lack of clinical symptoms al-
though detectable neutralizing antibodies were missing
at the time of infection [17]. Furthermore, a study on
Crimean-Congo hemorrhagic fever virus (CCHFV, fam-
ily Bunyaviridae, genus Nairovirus) reports that an inac-
tivated vaccine is able to elicit a considerable T-cell
reaction in humans as measured by IFN-gamma produc-
tion [18].
Unfortunately, there are no immunological studies avail-
able which deal with orthobunyavirus vaccines. Thus, the
exact mechanism underlying our observations remains
unclear. However, as saponins are able to stimulate cellu-
lar immune responses [19], this adjuvant used for the for-
mulation of the vaccine may be an important factor forvaccine efficacy and protection from SBV-replication post
challenge infection.
In conclusion, the present study demonstrated the
complete protection of sheep from SBV-infection after a
single injection while the underlying immunological
mechanism needs to be further investigated.
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